よむ、つかう、まなぶ。
04資料2-1_森野委員提出資料（おたふくかぜワクチンファクトシート第２版） (55 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_73851.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会 予防接種基本方針部会 ワクチン評価に関する小委員会（第34回 6／19）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
174.
Bryant K, McVernon J, Marchant C, et al. Immunogenicity and safety of measles-mumps-
rubella and varicella vaccines coadministered with a fourth dose of Haemophilus influenzae type b and
Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in toddlers: a pooled
analysis of randomized trials. Hum Vaccin Immunother 2012; 8(8): 1036–41.
175.
Blatter MM, Klein NP, Shepard JS, et al. Immunogenicity and safety of two tetravalent
(measles, mumps, rubella, varicella) vaccines coadministered with hepatitis a and pneumococcal
conjugate vaccines to children twelve to fourteen months of age. Pediatr Infect Dis J 2012; 31(8): e133–
40.
176.
Shinefield HR, Black SB, Staehle BO, et al. Safety, tolerability and immunogenicity of
concomitant injections in separate locations of M-M-R II, VARIVAX and TETRAMUNE in healthy
children vs. concomitant injections of M-M-R II and TETRAMUNE followed six weeks later by
VARIVAX. Pediatr Infect Dis J 1998; 17(11): 980–5.
177.
Hoshi SL, Kondo M, Okubo I. Economic evaluation of vaccination programme of mumps
vaccine to the birth cohort in Japan. Vaccine 2014; 32(33): 4189–97.
178.
Kitano T, Onaka M, Ishihara M, Nishiyama A, Hashimoto N, Yoshida S. Static model
simulation for routine mumps vaccination in Japan: with a result of mumps-related complications in a
Japanese community hospital. Clin Exp Vaccine Res 2017; 6(2): 120–7.
179.
Kitano T. Dynamic transmission model of routine mumps vaccination in Japan. Epidemiol
Infect 2018; 147: e60.
180.
Kitano T, Aoki H. The estimated impact of decreased childhood vaccination due to COVID-
19 using a dynamic transmission model of mumps in Japan. Hum Vaccin Immunother 2021; 17(5):
1313–6.
55
Bryant K, McVernon J, Marchant C, et al. Immunogenicity and safety of measles-mumps-
rubella and varicella vaccines coadministered with a fourth dose of Haemophilus influenzae type b and
Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in toddlers: a pooled
analysis of randomized trials. Hum Vaccin Immunother 2012; 8(8): 1036–41.
175.
Blatter MM, Klein NP, Shepard JS, et al. Immunogenicity and safety of two tetravalent
(measles, mumps, rubella, varicella) vaccines coadministered with hepatitis a and pneumococcal
conjugate vaccines to children twelve to fourteen months of age. Pediatr Infect Dis J 2012; 31(8): e133–
40.
176.
Shinefield HR, Black SB, Staehle BO, et al. Safety, tolerability and immunogenicity of
concomitant injections in separate locations of M-M-R II, VARIVAX and TETRAMUNE in healthy
children vs. concomitant injections of M-M-R II and TETRAMUNE followed six weeks later by
VARIVAX. Pediatr Infect Dis J 1998; 17(11): 980–5.
177.
Hoshi SL, Kondo M, Okubo I. Economic evaluation of vaccination programme of mumps
vaccine to the birth cohort in Japan. Vaccine 2014; 32(33): 4189–97.
178.
Kitano T, Onaka M, Ishihara M, Nishiyama A, Hashimoto N, Yoshida S. Static model
simulation for routine mumps vaccination in Japan: with a result of mumps-related complications in a
Japanese community hospital. Clin Exp Vaccine Res 2017; 6(2): 120–7.
179.
Kitano T. Dynamic transmission model of routine mumps vaccination in Japan. Epidemiol
Infect 2018; 147: e60.
180.
Kitano T, Aoki H. The estimated impact of decreased childhood vaccination due to COVID-
19 using a dynamic transmission model of mumps in Japan. Hum Vaccin Immunother 2021; 17(5):
1313–6.
55